Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL685364 | 1.00 | KMT2A (0.40) | KMT2AMEN1SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL20793996 | 0.85 | MEN1 (0.41) | KMT2AMEN1GAAMGAMSI | |
| SCHEMBL17873040 | 0.83 | SMYD3 (0.43) | KMT2AMEN1GAAMGAMSI | |
| SCHEMBL17873037 | 0.83 | SMYD3 (0.43) | KMT2AMEN1GAAMGAMSI | |
| SCHEMBL2721040 | 0.82 | — | — | |
| SCHEMBL21706896 | 0.81 | MEN1 (0.41) | KMT2AMEN1SMN1; SMN2GAARAB9A | |
| SCHEMBL20780375 | 0.81 | MEN1 (0.41) | KMT2AMEN1SMN1; SMN2GAARAB9A | |
| SCHEMBL29913904 | 0.81 | CYP1A2 (0.41) | KMT2AMEN1SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL28473023 | 0.80 | GAA (0.50) | KMT2AMEN1SMN1; SMN2GAAMGAM | |
| SCHEMBL175784 | 0.80 | PLG (0.47) | KMT2AMEN1CYP2C9GAAMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841478-B2 | Method for preparing trans-{4-[(alkylamino) methyl]- cyclohexyl}acetic acid ester | KOWA COMPANY, LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| US-8841478-B2 | Method for preparing trans-{4-[(alkylamino) methyl]- cyclohexyl}acetic acid ester | KOWA COMPANY, LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| US-20110288328-A1 | METHOD FOR PREPARING TRANS-ACETIC ACID ESTER | KOWA COMPANY, LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| US-7807701-B2 | Dibenzylamine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2010-10-05 | — | — | US | disclosed |
| WO-2010061621-A1 | METHOD FOR MANUFACTURING TRANS-{4-[(ALKYL AMINO) METHYL] CYCLOHEXYL} ACETIC ESTER | 興和株式会社 (JP) | 2010-06-03 | — | — | WO | disclosed |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. (JP) | 2008-06-19 | — | — | US | disclosed |
| US-7332514-B2 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2008-02-19 | — | — | US | disclosed |
| EP-1829858-A2 | Dibenzylamine compounds and pharmaceutical use thereof | Japan Tobacco, Inc. (JP) | 2007-09-05 | — | — | EP | disclosed |
| EP-1533292-B1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2007-02-14 | — | — | EP | disclosed |
| EP-1533292-A1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | CETP, CES1, APOB | KMT2A 971/4885MEN1 1354/4885SMN1; SMN2 4776/4885 |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | CETP, PCSK9, CES1 | KMT2A 1287/4885MEN1 1218/4885SMN1; SMN2 4792/4885 |
| US-20110288328-A1 | METHOD FOR PREPARING TRANS-ACETIC ACID ESTER | ACSL6, ACSL3, ACSL1 | KMT2A 4068/4885MEN1 691/4885SMN1; SMN2 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.